News Website

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers - The ASCO Post

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers The ASCO Post

Published: Aug. 6, 2025, 3:38 p.m.

Read Full Article

Real-World Study on Adverse Drug Reactions of Pembrolizumab in Endometrial Cancer Treatment: Insights from the FAERS Database - Frontiers

Real-World Study on Adverse Drug Reactions of Pembrolizumab in Endometrial Cancer Treatment: Insights from the FAERS Database Frontiers

Published: Aug. 6, 2025, 2:27 p.m.

Read Full Article

NICE approves first immunotherapy combination for endometrial cancer - Wired Gov

NICE approves first immunotherapy combination for endometrial cancer Wired Gov

Published: Aug. 6, 2025, 1:13 p.m.

Read Full Article

First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central

First immunotherapy combination for endometrial cancer approved by NICE Oncology Central

Published: Aug. 6, 2025, 11:18 a.m.

Read Full Article

New NHS Drug Option for Advanced Endometrial Cancer - Medscape

New NHS Drug Option for Advanced Endometrial Cancer Medscape

Published: Aug. 6, 2025, 10:54 a.m.

Read Full Article

NICE Recommends Keytruda Combination for First-Line Treatment of Advanced Endometrial Cancer - NAVLIN DAILY

NICE Recommends Keytruda Combination for First-Line Treatment of Advanced Endometrial Cancer NAVLIN DAILY

Published: Aug. 6, 2025, 9:30 a.m.

Read Full Article

First immunotherapy for advanced endometrial cancer approved in the UK - Open Access Government

First immunotherapy for advanced endometrial cancer approved in the UK Open Access Government

Published: Aug. 6, 2025, 8:50 a.m.

Read Full Article

NICE recommends Keytruda for endometrial cancer - The Pharma Letter

NICE recommends Keytruda for endometrial cancer The Pharma Letter

Published: Aug. 6, 2025, 6:49 a.m.

Read Full Article

Unraveling the Core of Endometriosis: The Impact of Endocrine Disruptors.

Globally, endometriosis affects almost 10% of reproductive-aged women, leading to chronic pain and discomfort. Endocrine-disrupting compounds (EDCs) seem to play a pivotal role as a causal factor. The current manuscript …

Published: Aug. 6, 2025, midnight

Read Full Article

chemicals endocrine-disrupting compounds endometriosis hormonal imbalance reproductive health

Harnessing the CD16-PI3Kγ axis in peritoneal CD14hi macrophages: A transformative approach to endometriosis management.

Endometriosis (EMS) is a prevalent estrogen-dependent gynecological disorder characterized by ectopic growth of endometrial tissue. Central to its pathophysiology, peritoneal CD14hi macrophages exhibit a pro-EMS phenotype and drive disease progression. …

Published: Aug. 6, 2025, midnight

Read Full Article

CD14(hi) macrophage CD16 Endometriosis PI3Kγ Pro-endometriosis effects

Latest Articles

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers - The ASCO Post

Real-World Study on Adverse Drug Reactions of Pembrolizumab in Endometrial Cancer Treatment: Insights from the FAERS Database - Frontiers

NICE approves first immunotherapy combination for endometrial cancer - Wired Gov

First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central

New NHS Drug Option for Advanced Endometrial Cancer - Medscape

NICE Recommends Keytruda Combination for First-Line Treatment of Advanced Endometrial Cancer - NAVLIN DAILY

First immunotherapy for advanced endometrial cancer approved in the UK - Open Access Government

NICE recommends Keytruda for endometrial cancer - The Pharma Letter

Unraveling the Core of Endometriosis: The Impact of Endocrine Disruptors.

Harnessing the CD16-PI3Kγ axis in peritoneal CD14hi macrophages: A transformative approach to endometriosis management.

Subscribe to Our Newsletter